tiprankstipranks
MiNK Therapeutics Appoints Dr. Robert Kadlec to Board
Company Announcements

MiNK Therapeutics Appoints Dr. Robert Kadlec to Board

Don't Miss our Black Friday Offers:

MiNK Therapeutics ( (INKT) ) has issued an announcement.

MiNK Therapeutics Inc. has appointed Dr. Robert Kadlec as a Class II director on its Board, with a term lasting until 2026. Dr. Kadlec’s role includes serving on the Corporate Governance and Nominating Committee, and he has been granted options to purchase shares of MiNK’s stock, vesting over three years. His compensation package includes both cash and equity, aligning with MiNK’s non-employee director program, and his appointment was formally announced via a press release.

For an in-depth examination of INKT stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyMiNK Therapeutics price target lowered to $4 from $8 at Baird
TipRanks Auto-Generated NewsdeskMiNK Therapeutics Reports Q3 Growth and Strategic Advances
TheFlyMiNK Therapeutics reports Q3 EPS (5c), consensus (8c)
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App